Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05657613 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects
A Phase 1 study, sponsored by CTI BioPharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT05657613: Completed Phase 1 study, sponsored by CTI BioPharma.
NCT05657613 is a Phase 1 study that has completed, run by CTI BioPharma. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05657613, a Phase 1 study, has completed, sponsored by CTI BioPharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, fixed-sequence, 2-part DDI study. Subjects will participate in only 1 study part.
Interventions
- DRUG CYP450 Cocktail and Transporter Substrates with Pacritinib
- DRUG Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib
- DRUG Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-01-03 |
| Est. Completion | 2023-06-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05657613
The ClinicalTrials.gov registry entry for NCT05657613 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CTI BioPharma, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CYP450 Cocktail and Transporter Substrates with Pacritinib is the first listed.
NCT05657613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05657613 about?
NCT05657613 is a clinical study titled "Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects". This is a Phase 1, open-label, fixed-sequence, 2-part DDI study. Subjects will participate in only 1 study part.
What is the current status of trial NCT05657613?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-01-03. Estimated completion is 2023-06-08.
What interventions are being tested in trial NCT05657613?
The interventions under investigation include: CYP450 Cocktail and Transporter Substrates with Pacritinib (DRUG), Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib (DRUG), Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib (DRUG).
Who is sponsoring clinical trial NCT05657613?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.